Második emlo{double acute}megtartó mu{double acute}tét és ismételt besugárzás szövetközi nagy dózisteljesítményu{double acute} brachyterá piával az emlo{double acute}rák lokális kiújulásának kezelésére - 5 éves eredmények

Csaba Polgár, Tibor Major, Zoltán Sulyok, Georgina Fröhlich, Éva Szabó, Ákos Sávolt, Zoltán Mátrai, László Tóth, János Fodor

Research output: Article

5 Citations (Scopus)

Abstract

The purpose of our work was to evaluate the efficacy of second breast-conserving surgery (BCS) and reirradiation with interstitial high-dose-rate (HDR) brachytherapy (BT) for the management of local recurrences. Between 1999 and 2010, fifteen patients initially treated for breast carcinoma by BCS and radiation therapy who had isolated intra-breast recurrence underwent second BCS and perioperative HDR multicatheter BT. Breast cancer related events, late side effects, and cosmetic results were assessed. At a median follow-up of 62 months (range: 11-127) second local recurrence has not occurred, yielding a 100% mastectomy-free survival. Four patients (27%) developed subsequent distant metastasis and died of breast cancer. The 5-year actuarial rate of disease-free and overall survival was 69% and 85%, respectively. Cosmetic results were rated excellent, good, fair, poor, and unknown in 1 (7%), 10 (66%), 2 (13%), 1 (7%), and 1 (7%) patients, respectively. Grade 2 fibrosis and skin toxicity occurred in 1 (7%) and 1 (7%) patients. Asymptomatic fat necrosis was detected in 9 (60%) women. No patient developed grade 3-4 late side effects. Second BCS followed by partial breast reirradiation is a safe and effective option for the management of selected patients developing intra-breast recurrence after previous breast-conserving therapy. Perioperative HDR BT may decrease the risk of second local relapse with acceptable cosmetic results and low rate of late side effects.

Original languageHungarian
Pages (from-to)68-74
Number of pages7
JournalMagyar Onkologia
Volume56
Issue number2
Publication statusPublished - 2012

Fingerprint

Segmental Mastectomy
Brachytherapy
Breast
Recurrence
Cosmetics
Breast Neoplasms
Fat Necrosis
Mastectomy
Disease-Free Survival
Re-Irradiation
Fibrosis
Radiotherapy
Neoplasm Metastasis
Skin
Survival

Keywords

  • Brachytherapy
  • Breast cancer
  • Local recurrence
  • Radiotherapy
  • Second breast-conserving surgery

ASJC Scopus subject areas

  • Oncology

Cite this

@article{bb765b2dfd1148c69d5c3832f0a22f18,
title = "M{\'a}sodik emlo{double acute}megtart{\'o} mu{double acute}t{\'e}t {\'e}s ism{\'e}telt besug{\'a}rz{\'a}s sz{\"o}vetk{\"o}zi nagy d{\'o}zisteljes{\'i}tm{\'e}nyu{double acute} brachyter{\'a} pi{\'a}val az emlo{double acute}r{\'a}k lok{\'a}lis ki{\'u}jul{\'a}s{\'a}nak kezel{\'e}s{\'e}re - 5 {\'e}ves eredm{\'e}nyek",
abstract = "The purpose of our work was to evaluate the efficacy of second breast-conserving surgery (BCS) and reirradiation with interstitial high-dose-rate (HDR) brachytherapy (BT) for the management of local recurrences. Between 1999 and 2010, fifteen patients initially treated for breast carcinoma by BCS and radiation therapy who had isolated intra-breast recurrence underwent second BCS and perioperative HDR multicatheter BT. Breast cancer related events, late side effects, and cosmetic results were assessed. At a median follow-up of 62 months (range: 11-127) second local recurrence has not occurred, yielding a 100{\%} mastectomy-free survival. Four patients (27{\%}) developed subsequent distant metastasis and died of breast cancer. The 5-year actuarial rate of disease-free and overall survival was 69{\%} and 85{\%}, respectively. Cosmetic results were rated excellent, good, fair, poor, and unknown in 1 (7{\%}), 10 (66{\%}), 2 (13{\%}), 1 (7{\%}), and 1 (7{\%}) patients, respectively. Grade 2 fibrosis and skin toxicity occurred in 1 (7{\%}) and 1 (7{\%}) patients. Asymptomatic fat necrosis was detected in 9 (60{\%}) women. No patient developed grade 3-4 late side effects. Second BCS followed by partial breast reirradiation is a safe and effective option for the management of selected patients developing intra-breast recurrence after previous breast-conserving therapy. Perioperative HDR BT may decrease the risk of second local relapse with acceptable cosmetic results and low rate of late side effects.",
keywords = "Brachytherapy, Breast cancer, Local recurrence, Radiotherapy, Second breast-conserving surgery",
author = "Csaba Polg{\'a}r and Tibor Major and Zolt{\'a}n Sulyok and Georgina Fr{\"o}hlich and {\'E}va Szab{\'o} and {\'A}kos S{\'a}volt and Zolt{\'a}n M{\'a}trai and L{\'a}szl{\'o} T{\'o}th and J{\'a}nos Fodor",
year = "2012",
language = "Hungarian",
volume = "56",
pages = "68--74",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Második emlo{double acute}megtartó mu{double acute}tét és ismételt besugárzás szövetközi nagy dózisteljesítményu{double acute} brachyterá piával az emlo{double acute}rák lokális kiújulásának kezelésére - 5 éves eredmények

AU - Polgár, Csaba

AU - Major, Tibor

AU - Sulyok, Zoltán

AU - Fröhlich, Georgina

AU - Szabó, Éva

AU - Sávolt, Ákos

AU - Mátrai, Zoltán

AU - Tóth, László

AU - Fodor, János

PY - 2012

Y1 - 2012

N2 - The purpose of our work was to evaluate the efficacy of second breast-conserving surgery (BCS) and reirradiation with interstitial high-dose-rate (HDR) brachytherapy (BT) for the management of local recurrences. Between 1999 and 2010, fifteen patients initially treated for breast carcinoma by BCS and radiation therapy who had isolated intra-breast recurrence underwent second BCS and perioperative HDR multicatheter BT. Breast cancer related events, late side effects, and cosmetic results were assessed. At a median follow-up of 62 months (range: 11-127) second local recurrence has not occurred, yielding a 100% mastectomy-free survival. Four patients (27%) developed subsequent distant metastasis and died of breast cancer. The 5-year actuarial rate of disease-free and overall survival was 69% and 85%, respectively. Cosmetic results were rated excellent, good, fair, poor, and unknown in 1 (7%), 10 (66%), 2 (13%), 1 (7%), and 1 (7%) patients, respectively. Grade 2 fibrosis and skin toxicity occurred in 1 (7%) and 1 (7%) patients. Asymptomatic fat necrosis was detected in 9 (60%) women. No patient developed grade 3-4 late side effects. Second BCS followed by partial breast reirradiation is a safe and effective option for the management of selected patients developing intra-breast recurrence after previous breast-conserving therapy. Perioperative HDR BT may decrease the risk of second local relapse with acceptable cosmetic results and low rate of late side effects.

AB - The purpose of our work was to evaluate the efficacy of second breast-conserving surgery (BCS) and reirradiation with interstitial high-dose-rate (HDR) brachytherapy (BT) for the management of local recurrences. Between 1999 and 2010, fifteen patients initially treated for breast carcinoma by BCS and radiation therapy who had isolated intra-breast recurrence underwent second BCS and perioperative HDR multicatheter BT. Breast cancer related events, late side effects, and cosmetic results were assessed. At a median follow-up of 62 months (range: 11-127) second local recurrence has not occurred, yielding a 100% mastectomy-free survival. Four patients (27%) developed subsequent distant metastasis and died of breast cancer. The 5-year actuarial rate of disease-free and overall survival was 69% and 85%, respectively. Cosmetic results were rated excellent, good, fair, poor, and unknown in 1 (7%), 10 (66%), 2 (13%), 1 (7%), and 1 (7%) patients, respectively. Grade 2 fibrosis and skin toxicity occurred in 1 (7%) and 1 (7%) patients. Asymptomatic fat necrosis was detected in 9 (60%) women. No patient developed grade 3-4 late side effects. Second BCS followed by partial breast reirradiation is a safe and effective option for the management of selected patients developing intra-breast recurrence after previous breast-conserving therapy. Perioperative HDR BT may decrease the risk of second local relapse with acceptable cosmetic results and low rate of late side effects.

KW - Brachytherapy

KW - Breast cancer

KW - Local recurrence

KW - Radiotherapy

KW - Second breast-conserving surgery

UR - http://www.scopus.com/inward/record.url?scp=84863766311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863766311&partnerID=8YFLogxK

M3 - Article

C2 - 22629542

AN - SCOPUS:84863766311

VL - 56

SP - 68

EP - 74

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -